In 2014, CPX-351, a new encapsulated drug with a 5:1 ratio of cytarabine and daunorubicin was run in parallel with the standard treatment protocol (7 + 3 regimen) in newly diagnosed elderly NPM1-mutated AML individuals. The gene discussed is NPM1; the disease is acute myeloid leukemia.